Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Black Phoenix Black Phoenix +35.69%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.14%
#4 Akedo Akedo +15.19%
#5 HOME HOME +13.37%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.89%
#7 Fake World Assets Fake World Assets +12.51%
#8 clBTC clBTC +11.92%
#9 Arowana Arowana +11.04%
#10 OpenEden OpenEden +8.62%
Coin of the day
Islamic Coin Islamic Coin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Peringkat dalam Saham #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Harga Saham
$0.00366968
Terakhir disinkronkan: 2024-07-23
Kapitalisasi Pasar
$291.42K
Perubahan (1 hari)
-0.81%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Bioasis Technologies Inc. (BTI)

Kategori

Healthcare
Pendapatan untuk Bioasis Technologies Inc. (BTI)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Bioasis Technologies Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Bioasis Technologies Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE